XNAS
SCLXW
Market cap36mUSD
Jun 26, Last price
0.10USD
1D
14.71%
1Q
4.40%
IPO
-33.10%
Name
Scilex Holding Co
Chart & Performance
P/E
—
P/S
0.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-1.45%
Rev. gr., 5y
21.89%
Revenues
57m
+21.07%
Net income
-73m
L-36.32%
CFO
19m
P
Profile
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 56,590 21.07% | 46,743 22.90% | 38,034 21.45% | |||
Cost of revenue | 26,330 | 28,427 | 19,851 | |||
Unusual Expense (Income) | ||||||
NOPBT | 30,260 | 18,316 | 18,183 | |||
NOPBT Margin | 53.47% | 39.18% | 47.81% | |||
Operating Taxes | (1,000) | 13 | 4 | |||
Tax Rate | 0.07% | 0.02% | ||||
NOPAT | 30,261 | 18,303 | 18,179 | |||
Net income | (72,807) -36.32% | (114,331) 389.35% | (23,364) -73.58% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 44,638 | (10,000) | 96 | |||
BB yield | -79.83% | 3.76% | -0.02% | |||
| Debt | ||||||
Debt current | 35,590 | 109,947 | 745 | |||
Long-term debt | 3,760 | 22,271 | 2,075 | |||
Deferred revenue | ||||||
Other long-term liabilities | 24,436 | 4,592 | 4,781 | |||
Net debt | 33,658 | 128,297 | 636 | |||
| Cash flow | ||||||
Cash from operating activities | 19,349 | (20,707) | (21,258) | |||
CAPEX | (30) | (2,067) | ||||
Cash from investing activities | (2,675) | (330) | (2,067) | |||
Cash from financing activities | (18,131) | 23,582 | 21,171 | |||
FCF | 120,415 | 94,252 | (55,486) | |||
| Balance | ||||||
Cash | 3,272 | 3,921 | 2,184 | |||
Long term investments | 2,420 | |||||
Excess cash | 2,862 | 1,584 | 282 | |||
Stockholders' equity | (556,711) | (490,229) | (375,897) | |||
Invested Capital | 425,619 | 451,105 | 418,327 | |||
ROIC | 6.90% | 4.21% | 4.90% | |||
ROCE | 42.85% | |||||
| EV | ||||||
Common stock shares outstanding | 131,136 | 130,298 | 134,226 | |||
Price | 0.43 -79.10% | 2.04 -48.87% | 3.99 | |||
Market cap | 55,916 -78.96% | 265,808 -50.37% | 535,562 | |||
EV | 89,574 | 394,105 | 536,201 | |||
EBITDA | 34,306 | 22,462 | 22,144 | |||
EV/EBITDA | 2.61 | 17.55 | 24.21 | |||
Interest | 1,963 | 1,068 | 9,604 | |||
Interest/NOPBT | 6.49% | 5.83% | 52.82% | |||